A vaccine known as BNT162b1 creates antibodies that respond at the same level. Or above the level seen in any disease-recovery serum In relatively small doses of medication According to Ugur Sahin, CEO of Bio-Tech.
The recovery serum is the blood of the patients recovered from Covid-19.
This preliminary data comes from an experiment known as Phase 1/2, which aims to show that the vaccine is non-toxic. And stimulate the response of the immune system to prepare the body to fight against viruses
In this study, 45 participants aged between 18 and 55 were given 10 doses, 30 or 100 micrograms, 2 days apart, some were actually vaccinated, and some received doses. pseudo
Pfizer revealed that Volunteers who were vaccinated with 10 or 30 micrograms would cause the body to produce antibodies. Which is important in preventing the virus, Covid-19, and states that the vaccine does not cause side effects to the subjects in any way.
From the educational data uploaded to medrxiv.org website before being distributed to the public. It was found that quite a high number of participants had fever after receiving the second dose of the dose, but it was expected. And not seen as an obstacle
The vaccine relies on the genetic material of the Covid-19 virus, called Messenger RNA, a genetic code that penetrates human cells. Making it an antigen that is specifically tailored for the new species of coronary virus
Currently, many organizations, both public and private sectors around the world Are competing to find ways to treat and prevent this deadly disease While from the College of Health and Tropical Medicine University of london Found that a total of 23 vaccine vaccine projects that have entered clinical trials with humans
Many projects go to stage 2 or 3 of the trial, where they inject vaccines to thousands of volunteers to assess their effectiveness. Observe the impact and gather other information. That will open the way for those vaccines to be used safely
No comments:
Post a Comment